Schulich school of Medicine and Dentistry logo Minimally-Invasive Cardiac Surgical Procedures Schulich Medicine & Dentistry

LHSC Heart Team shares insights on the first North American experience with the Engager self-expanding transcatheter aortic valve

Ann Thorac Surg. 2016 Aug;102(2):e167-71.

First North American Experience With the Engager Self-Expanding Transcatheter Aortic Valve: Insights From the London Health Sciences Centre Heart Team

Bagur R, Kiaii B, Teefy PJ, Diamantouros P, Lavi R, Harle C, Cassese M, Chu MW.


The Engager aortic bioprosthesis consists of bovine pericardial leaflets mounted on a self-expandable frame with unique anatomic orientation capabilities to engage the aortic valve cusps. We report the initial North American transcatheter aortic valve implantation (TAVI) experience with the Engager device. Transapical TAVI was performed in 4 patients (mean age 80 +/- 6 years, Society of Thoracic Surgeons score 5 +/- 1%). The valve was anatomically oriented and successfully implanted in all patients. There were no conversions to open operation or major procedure-related adverse events. Pacemaker implantation was necessary in 1 patient. None of the patients showed paravalvular leak. The Engager device for TAVI provides anatomic orientation and anchoring that prevents coronary obstruction and paravalvular leak.

Copyright © 2016 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Read the article in PubMed